Onconetix, Inc.
ONCO evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ONCO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ONCO
Onconetix, Inc. is a commercial-stage biotechnology company focused on the commercialization of Proclarix, a diagnostic product for prostate cancer, while also developing ONC-392 for non-small cell lung cancer; the company faces significant financial challenges and has a going concern warning.
Key risk: Going concern uncertainty
BioSniper Score
Based on 6 of 6 signals
Market Cap
$2.4M
Cash Runway
9.6 moLead Asset
entadfi (Approved)
Next Catalyst
Phase3_Topline · Aug 31, 2028Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 1 catalyst for Onconetix, Inc..
Onconetix, Inc. is a commercial-stage biotechnology company focused on the commercialization of Proclarix, a diagnostic product for prostate cancer, while also developing ONC-392 for non-small cell lung cancer; the company faces significant financial challenges and has a going concern warning.
- Cash & equivalents of $5.9M as of 2026-06-30 [sec].
- Net loss of $2.9M for the quarter ended 2026-06-30 [sec].
- Accumulated deficit of approximately $135.4M as of 2026-03-31 [sec_mda].
- Total revenue of $0.0M as of 2026-06-30 [sec].
- Going concern warning: substantial doubt about ability to continue as a going concern [sec_mda].
What works
- Proclarix is a commercial-stage diagnostic product for prostate cancer, providing a potential revenue stream [sec].
- The company has a Phase 3 trial for ONC-392 in metastatic non-small cell lung cancer, with topline data expected in 2028 [catalyst_timeline].
- Recent Series D and E PIPE financings in 2025 provided additional cash to support near-term operations [sec].
What to weigh
- The company has incurred net losses since inception and expects to continue incurring operating losses [sec].
- Cash of $5.9M as of 2026-06-30 is insufficient to fund operations through the end of 2026 [sec_mda].
- There is substantial doubt about the company's ability to continue as a going concern [sec_mda].
- No committed sources of financing exist beyond the equity facility, and additional funding may not be available on favorable terms [sec].
From the filings
Quoted directly from source documents.
Going concern warning
“These factors raise substantial doubt about the Company's ability to continue as a going concern for one year from the date of issuance of the consolidated financial statements for the year ended December 31, 2025.”
SEC MD&A · March 13, 2026
Cash position as of March 31, 2026
“As of March 31, 2026, the Company had cash of approximately $3.7 million, a working capital surplus of approximately $1.3 million and an accumulated deficit of approximately $135.4 million.”
SEC MD&A · May 13, 2026
Need for additional capital
“We will continue to require significant additional capital to commercialize Proclarix, and to fund operations for the foreseeable future.”
SEC filings · August 12, 2026
No committed financing sources
“there are currently no committed sources of financing, and there is no assurance that additional funding will be available on favorable terms, if at all.”
SEC filings · June 9, 2026
Catalyst timeline
- 2028-08-31 · Phase3_Topline · onc-392 — Phase 3 Topline: Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung C — Topline results from the Phase 3 trial of ONC-392 in metastatic non-small cell lung cancer are expected, which could impact the company's pipeline value.
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Substantial doubt about ability to continue as a going concern; may need to curtail operations if funding not secured [sec_mda].
- Cash runway insufficient — Cash of $5.9M as of 2026-06-30 not sufficient to fund operations through end of 2026 [sec_mda].
- No committed financing — No committed sources of financing beyond equity facility; future funding uncertain [sec].
- Dependence on Proclarix commercialization — Proclarix still subject to further development and commercialization; no sustained revenue yet [sec].
What to watch
- Ability to secure additional financing to extend cash runway beyond 2026 [sec].
- Commercialization progress and revenue generation from Proclarix [sec].
- Phase 3 topline data for ONC-392 expected in 2028 [catalyst_timeline].
- Any updates on going concern resolution or strategic partnerships [sec_mda].
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Onconetix, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Onconetix, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
9.6 months
D/E 0.22 · 0% dilution
Lead: Approved
2 candidates
1 upcoming, next in ~732d
3 buys · 3 sells (180d)
Runway
Catalysts
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
2
Total value held
$20K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 11,854 | $18K |
| citigroup inc | 1,717 | $3K |
Short Interest
as of Apr 28, 2026- % of float
- 33.1%
- Days to cover
- 0.0
- Shares short
- 228,855
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ONCO short interestFrequently asked questions
What is the AI investment thesis for Onconetix, Inc.?
Onconetix, Inc. is a commercial-stage biotechnology company focused on the commercialization of Proclarix, a diagnostic product for prostate cancer, while also developing ONC-392 for non-small cell lung cancer; the company faces significant financial challenges and has a going concern warning.
What is Onconetix, Inc.'s lead drug candidate?
Onconetix, Inc.'s most advanced tracked candidate is entadfi (Approved) for BPH (benign prostatic hyperplasia).
What is Onconetix, Inc.'s next catalyst?
Onconetix, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung C" — expected August 31, 2028.
Who is the CEO of Onconetix, Inc.?
Mr. David Allan White C.A., C.P.A., ICD.D is the chief executive officer of Onconetix, Inc. (ONCO).
Where is Onconetix, Inc. headquartered?
Onconetix, Inc. (ONCO) is headquartered in Cincinnati, OH, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.